Endocrine Abstracts

Introduction: In our setting, it is quite common that control of major risk factors of patients with type 2 diabetes (T2D) after myocardial infarction (MI) is not made by specific risk factors units (SRFU). Here, we conducted a preliminary study to investigate the effects of a SRFU intervention on metabolic and cardiovascular outcomes in T2D patients who suffered from MI.

Methods/design: This retrospective and observational study was performed in one single centre. Data related to metabolic and cardiologic variables were collected at discharge and at 6 and 12 months of follow-up. Variables were compared according to whether risk factors control was made by SRFU or other specialties after discharge.

Results: Data from forty-eight patients (mean age: 70.6±8.7 years; 47.9% females) were collected. 27.5% were referred to SRFU after discharge. Antidiabetic treatment was changed in 48.7%. Among patients whose treatment was changed, add-on strategy was the most used way to switch it (63.2%). Patients referred to SRFU were more likely to undergo changes in treatment (81.8% vs 35.7%; P=0.01). A1C reductions were higher among patients under SRFU control at 6 and 1 year (−0.74% vs −0.69% and −0.92% vs −0.65%, respectively). Also, rates of new hospitalizations due to heart failure at 6 and 12 months (18.2% vs 21%; 0% vs 5.5%) and mortality by any cause (0% vs 13%; 0% vs 5.5%), were lower in SRFU group. Nevertheless, non-significant differences were observed between groups.

Conclusions: Our results show a non-significant trend toward to improvement of metabolic and cardiovascular outcomes among patients that were referred to SRFU after MI. These differences were more remarkable when follow-up time was longer. Though further studies with a larger number of patients are ongoing in our Hospital, we conclude that referrals to a SRFU should be recommended in these patients.